Ilana Schlam
@ilanaschlam.bsky.social
Breast medical oncologist @Dana-Farber | Harvard | Posts are my own and not medical advise
The BRIDGES study @JCO GO
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
December 20, 2024 at 9:12 PM
The BRIDGES study @JCO GO
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 8:08 PM
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
December 12, 2024 at 5:57 PM
PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies
Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social
December 12, 2024 at 1:50 PM
Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social
Stellar discussion by Dr Burstein
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
December 11, 2024 at 3:58 PM
Stellar discussion by Dr Burstein
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
on the important findings of EMBER-3 presented by
Dr Jhaveri
Some important clinical questions:
❓how to incorporate these findings in clinic - with the approval of inavo-?
❓are we ready for ADC post ADC?
❓how to sequence these agents?
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
November 17, 2024 at 11:04 PM
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!